

18 December 2017

NSX Announcement

Completion of Capital Raising and Issue of Shares

Beroni Group Limited (“Beroni” or the “Company”) has today issued 5,796,597 fully paid ordinary shares in the Company (“Shares”) at an issue price \$0.54 each pursuant to the Placement offer (“Placement”) made to a sophisticated investor raising approximately \$3.1 million, without disclosure under Part 6D.2 of the Corporations Act. The new Shares are subject to voluntary escrow for a period of 12 months from date of issue.

Funds raised from the issue of Shares are for general working capital purposes, which may include potential research projects with Nankai University and the potential investment in Cystemix Pty Limited (an associated entity of the University of New South Wales) (“Cystemix”). Please see the Company’s announcement dated 2 November 2017 for information related to Cystemix and the letter of intent with UNSW.

Notice given under section 708A(5) of the Corporations Act 2001 (Cth)

This notice is given by the Company under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue of 5,796,597 fully paid shares by the Company without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, the Company has complied with:

1. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
2. section 674 of the Corporations Act.

There is no excluded information as at the date of this notice, for the purposes of Section 708A (7) and (8) of the Corporations Act.

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Non-Executive Director
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX: BTG)

Beroni Group’s currently has four main products: NicoBloc, Fogibloc, Multi Vigorous tablets (Bei Jingli) and Multi lung cleaning tablets (Bei Feiqing). Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries. The Company is open to acquisition opportunities to expand the business and increase its market share.